{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.4","upperLimit":"81.1","value":"69.9"},{"groupId":"OG001","lowerLimit":"60.3","upperLimit":"83.2","value":"72.5"}]}],"title":"180 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.2","upperLimit":"74.3","value":"62.1"},{"groupId":"OG001","lowerLimit":"54.9","upperLimit":"79","value":"67.5"}]}],"title":"365 days"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Time from HCT until the documentation of disease progression / relapse or death due to any cause, whichever occurs first. Progression-free survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"180 days and 365 days post-transplant","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}